The National Comprehensive Cancer Network® (NCCN®) is pleased to introduce a new analytic and evaluative information product, NCCN Oncology Insights Reports™. Herein, we present the first in the series, The NCCN Oncology Insights Report on Non-Small Cell Lung Cancer (NSCLC). This and subsequent NCCN Reports are intended to communicate to interested constituencies in the cancer community the views of thought leaders on the types and quanta of data and the study design or analysis deemed cogent and persuasive in making recommendations about appropriate treatments across the spectrum of decision-making processes. NCCN Reports address issues along the continuum of care as decisions and recommendations are made for early stage disease through recurrence and metastasis into surveillance and then palliation.
The NCCN views the availability of our new information product as yet another step in ongoing collaborations that foster innovation and acceptance of improved health care technologies. We believe that NCCN Reports will expand the dialogue and thus, better meet the needs of patients whom we serve.
Below we’ve provided you with some frequently asked questions about NCCN Reports to inform your decision to invest in this offering:
Who should be interested in the NCCN Report on NSCLC?
The audience for the NCCN Reports is any organization with an interest and investment in timely and relevant insights into cancer care.
What will the NCCN Report on NSCLC provide to me and/or my organization?
The NCCN Report on NSCLC will provide unique expert insight into areas such as clinical trial design, current and future trends in treatment, and the importance of biomarkers by placing unparalleled access to expert judgment at your fingertips. For additional value, subscribers will receive updates if important issues arise within the 12 month period after the Report is obtained. Further, subscribers will have the option to pose customized questions to the NCCN to enhance their use of the Report.
For more details, please see the Overview of NCCN Oncology Insights Reports on the following page.
How can I or someone within my organization purchase the NCCN Report on NSCLC?
NCCN has partnered with Oncology Reimbursement Management to distribute this offering. Please contact:
Ron Schleif, Oncology Reimbursement Management
11550 North Meridian Suite 101
Carmel, IN 46032
Because of the many advances in cancer research (molecular biology, genetics, biologics, etc.), the understanding of the complexity underlying the diseases of cancer has grown exponentially over the past decade. In parallel, advances in diagnostics and treatments for NSCLC have led to better outcomes and higher standards of what outcomes are expected.
These new understandings and treatments have raised multiple new questions and issues with regard to the decisions on the appropriate treatment of NSCLC patients. Among the areas to be explored in the report:
Insights to issues, data and information that will drive clinical development and discussion now and over the next 3 to 5 years on how decision-making regarding the appropriate diagnosis and treatment of NSCLC will change.
NCCN has brought together a team of NSCLC experts to provide insights on the evaluation and incorporation of diagnostics and therapeutics into recommendations for appropriate use in NSCLC patients.
|Chair:||David Ettinger, MD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
|Members:||Wallace Akerley, MD
Huntsman Cancer Institute at the University of Utah
|Mark Kris, MD
Memorial Sloan-Kettering Cancer Center
|Gregory Otterson, MD
The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute
|George Simon, MD
Fox Chase Cancer Center
|Purchase Prior to November 15, 2010 - $85,000|
|Purchase After November 15, 2010 - $100,000|
NCCN Reports are solely for internal organization use. Prior to receiving the report, all parties must sign an End User Agreement.